Catalog No.: PC-22054Not For Human Use, Lab Use Only.
CBPD-409 (CBPD409) is a highly potent, selective, and orally bioavailable CBP/p300 degrader with DC50 0.2-0.4 nM in VCaP, LNCaP, and 22Rv1 AR+ prostate cancer cell lines.
CBPD-409 (CBPD409) is a highly potent, selective, and orally bioavailable CBP/p300degrader with DC50 0.2-0.4 nM in VCaP, LNCaP, and 22Rv1 AR+ prostate cancer cell lines.
CBPD-409displays strong antiproliferative effects with IC50 1.2-2.0 nM in the VCaP, LNCaP, and 22Rv1 AR+ prostate cancer cell lines.
CBPD-409 at 1 mg/kg achieves >95% depletion of CBP/p300 proteins in the VCaP tumor tissue.
CBPD-409 exhibits strong tumor growth inhibition and is much more potent and efficacious thanCBP/p300 inhibitors CCS1477 and GNE-049 and the AR antagonist Enzalutamide.
